This study is currently recruiting participants.
National Cancer Institute (NCI)
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 3 Years Max Age: 35 Years
Referral Letter Required
Children/young adults; CD33CART cells
Leukemia; Neoplasms by Histologic Type; Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Myeloid
lentivirally-transduced CD33-redirected CAR-T cells (CD33CART)
Biological/Vaccine: CD33CART cell infusion
National Cancer Institute
The T cells of a person s immune system can be changed to fight cancer. This is called gene therapy. In this study, T cells will be changed to attack the CD33 marker. This marker is common in acute myeloid leukemia (AML). These new cells are called CD33CART cells. Researchers want to see if this therapy can treat AML that is not responding to standard therapy or has recurred after prior treatment.
To learn if CD33CART cells are safe for people with AML.
People ages 3-35 years who have AML with the CD33 marker, whose AML has not been cured with standard therapy
Participants will be screened with some or all of the following:
-blood and urine tests
-heart, liver, and lung tests
-assessment of well-being and ability to perform daily activities
-MRI, CT, or PET
-bone marrow biopsy or aspiration
Some screening tests will be repeated throughout the study.
Participants will have T cells taken. For this, needles are put in 2 different veins or the patient will have a central line placed. Blood is taken from one vein. A machine separates the T cells from the other parts of the blood. The rest of the blood is returned to the other vein.
Participants will get 2 chemotherapy drugs by IV for 3 days. Two days later they will get CD33CART cells by IV. They will have blood tests daily for 14 days and then at least twice weekly for 14 days.
Participants will take neurologic tests and fill out questionnaires.
Participants will have follow-up visits at months 2, 3, 6, 9, 18, and 24, then yearly for 5 years. They will be monitored for 15 years.
--Back to Top--
Eligibility: Subjects >=3 year to <=35 years of age with AML in 2nd or greater relapse or refractory to 2 or more induction attempts without central nervous system (CNS) CNS3 disease and who have a suitable allogeneic HCT donor and a performance status of >= 50% may be eligible for study.
Subjects >=3 year to <=35 years of age with AML in 2nd or greater relapse or refractory to 2 or more induction attempts without central nervous system (CNS) CNS3 disease and who have a suitable allogeneic HCT donor and a performance status of >= 50% may be eligible for study.
For more information: